Press release
Prostate Cancer Pipeline Analysis and Clinical Trials Assessment, 2025 by DelveInsight | Pfizer, Janssen Pharmaceutical, POINT Biopharma, Tavanta Therapeutics, Exelixis, Astellas Pharma Inc., Antev, ORCA Therapeutics, Regeneron Pharmaceuticals, Silenseed
Prostate Cancer Pipeline Analysis 2025 by DelveInsight
Prostate Cancer Overview:
Prostate cancer develops when cells in the prostate gland begin to grow uncontrollably. The prostate, a gland found only in men, produces some of the fluid in semen. The primary cause of prostate cancer is changes in the DNA, which result from mutations. Typically, prostate cancer is diagnosed when it has progressed to a later stage and symptoms become apparent. However, early screening tests can detect the cancer before any symptoms arise.
Download our report @ https://www.delveinsight.com/report-store/prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
"Prostate Cancer Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Prostate Cancer Therapeutics Market.
Key Takeaways from the Prostate Cancer Pipeline Report
DelveInsight's Prostate Cancer pipeline report depicts a robust space with 140+ active players working to develop 150+ pipeline therapies for Prostate Cancer treatment.
On February 12, 2025, BioXcel Therapeutics, Inc. announced that the FDA granted Fast Track designation for BXCL701 in combination with a checkpoint inhibitor (CPI) to treat metastatic small cell neuroendocrine prostate cancer (SCNC) in patients progressing on chemotherapy. This designation allows for expedited development and review by the FDA.
In September 2024, Ipsen revealed that the Phase III CONTACT-02 trial for Cabometyx® and atezolizumab in metastatic castration-resistant prostate cancer (mCRPC) showed a non-significant improvement in overall survival but achieved the progression-free survival (PFS) endpoint.
In September 2024, Foundation Medicine received FDA approval for FoundationOne®CDx and Liquid CDx as companion diagnostics for Lynparza® in BRCA-mutated mCRPC.
In July 2024, the ARANOTE trial demonstrated that NUBEQA® combined with androgen deprivation therapy (ADT) significantly improved radiological PFS in metastatic hormone-sensitive castrate-resistant prostate cancer (mHSPC).
In July 2024, the FDA granted fast-track designation to SYNC-T SV-102 for metastatic castration-resistant prostate cancer (mCRPC).
In June 2024, Kangpu Biopharmaceuticals received FDA approval for a Phase II/III trial of KPG-121 with Abiraterone for mCRPC.
In May 2024, Fusion Pharmaceuticals initiated the Phase 2 AlphaBreak trial of FPI-2265 in mCRPC patients.
In April 2024, Astellas Pharma obtained European approval for XTANDITM in high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer (nmHSPC).
In April 2024, FibroGen announced positive Phase 1 trial results for FG-3246 in mCRPC.
Key Prostate Cancer companies such as Pfizer, Janssen Pharmaceutical, POINT Biopharma, Tavanta Therapeutics, Exelixis, Astellas Pharma Inc., Antev, ORCA Therapeutics, Regeneron Pharmaceuticals, Silenseed LTD, Lantheus, Pantarhei Oncology, Zenith Epigenetics, Merck Sharp & Dohme, Bivision Pharmaceuticals, Oncternal Therapeutics, Amunix, FutureChem, Amgen, Taiho Oncology, Harpoon Therapeutics, Arvinas Androgen Receptor Inc., BioNTech SE, Nova Therapeutics, Qilu Pharmaceutical Co., Ltd., Ambrx, Janssen Research & Development, LLC, ORIC Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Clarity Pharmaceuticals Ltd., Vaccitech (UK) Limited, Orion Pharma, Hinova Pharmaceuticals, Cellbion Co., Ltd., and others are evaluating new drugs for Prostate Cancer to improve the treatment landscape.
Promising Prostate Cancer pipeline therapies in various stages of development include Niraparib, ZEN 3694, Ladiratuzumab, FOR46, REGN5678, and others.
Prostate Cancer Pipeline Analysis
The Prostate Cancer pipeline insights report 2025, provides insights into:
Provides comprehensive insights into key companies developing therapies in the Prostate Cancer Market.
Categorizes Prostate Cancer therapeutic companies by development stage: early, mid, and late-stage.
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
Reviews emerging Prostate Cancer drugs under development based on:
Stage of development
Prostate Cancer Route of administration
Target receptor
Monotherapy vs. combination therapy
Prostate Cancer Mechanism of action
Molecular type
Offers detailed analysis of:
Company-to-company and company-academia collaborations
Prostate Cancer Licensing agreements
Funding and investment activities supporting future Prostate Cancer market advancement.
Request for a sample report @ https://www.delveinsight.com/sample-request/prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Prostate Cancer Emerging Drugs
Niraparib: Janssen Research & Development
ZEN 3694: Zenith Epigenetics
Ladiratuzumab vedotin: Seagen
FOR46: Fortis Therapeutics
REGN5678: Regeneron Pharmaceuticals
Prostate Cancer Companies
There are over 140 key companies working on therapies for prostate cancer. Among them, Janssen Research & Development has its drug candidates in the most advanced stage, Phase III.
DelveInsight's report covers around 150+ products under different phases of Prostate Cancer clinical trials like
Prostate Cancer Late stage Therapies (Phase III)
Prostate Cancer Mid-stage Therapies (Phase II)
Prostate Cancer Early-stage Therapies (Phase I)
Prostate Cancer Pre-clinical and Prostate Cancer Discovery stage Therapies
Prostate Cancer Discontinued & Inactive Therapies
Prostate Cancer pipeline report provides the Prostate Cancer therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intravenous
Subcutaneous
Oral
Intramuscular
Prostate Cancer Products have been categorized under various Molecule types such as
Monoclonal antibody
Small molecule
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Prostate Cancer Therapies and Key Prostate Cancer Companies: Prostate Cancer Clinical Trials and recent advancements https://www.delveinsight.com/report-store/prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Prostate Cancer Pipeline Therapeutic Assessment
• Prostate Cancer Assessment by Product Type
• Prostate Cancer By Stage
• Prostate Cancer Assessment by Route of Administration
• Prostate Cancer Assessment by Molecule Type
Download Prostate Cancer Sample report to know in detail about the Prostate Cancer treatment market @ Prostate Cancer Therapeutic Assessment https://www.delveinsight.com/sample-request/prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Prostate Cancer Current Treatment Patterns
4. Prostate Cancer - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Prostate Cancer Late-Stage Products (Phase-III)
7. Prostate Cancer Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Prostate Cancer Discontinued Products
13. Prostate Cancer Product Profiles
14. Prostate Cancer Key Companies
15. Prostate Cancer Key Products
16. Dormant and Discontinued Products
17. Prostate Cancer Unmet Needs
18. Prostate Cancer Future Perspectives
19. Prostate Cancer Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Prostate Cancer Pipeline Reports Offerings: https://www.delveinsight.com/report-store/prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Prostate Cancer Pipeline Analysis and Clinical Trials Assessment, 2025 by DelveInsight | Pfizer, Janssen Pharmaceutical, POINT Biopharma, Tavanta Therapeutics, Exelixis, Astellas Pharma Inc., Antev, ORCA Therapeutics, Regeneron Pharmaceuticals, Silenseed here
News-ID: 3965929 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Prostate
The 3D Urology and Prostate Clinics Introduces Innovative Natural and Targeted P …
The 3D Urology and Prostate Clinics introduces its innovative 3D targeted injection therapies, offering effective, natural solutions for various prostate conditions including prostatitis, enlarged prostate, and prostate cancer.
Renowned for its pioneering approach to prostate health, The 3D Urology and Prostate Clinics is bringing renewed hope to patients worldwide suffering from various prostate diseases. Utilizing advanced diagnostic techniques and a unique targeted injection method, the clinics offer specialized treatments that focus…
The 3D Urology and Prostate Clinics Introduces Advanced 3D Prostate Targeted Tre …
The 3D Urology and Prostate Clinics announces its latest breakthrough in targeted prostate treatment, offering a revolutionary approach to prostate cancer and other prostate-related conditions.
The 3D Urology and Prostate Clinics, renowned for its advanced techniques in prostate health, is proud to present its groundbreaking 3D prostate Targeted Treatment, a comprehensive and non-invasive solution for men suffering from prostate conditions. The clinic's innovative treatment is designed to target the root causes…
The 3D Urology and Prostate Clinics Unveil Innovative 3D Prostate Targeted Treat …
The 3D Urology and Prostate Clinics introduce their groundbreaking 3D prostate targeted treatment, offering a non-invasive solution for prostate health issues.
The 3D Urology and Prostate Clinics, renowned for their specialized treatments in prostate health, are proud to unveil their innovative 3D prostate targeted treatment. This cutting-edge therapy provides a non-invasive, highly effective solution for prostate-related conditions, offering patients a new path to recovery and well-being.Image: https://i.imgur.com/NCfbb6S.jpg
At the heart of this…
The 3D Urology and Prostate Clinics Unveils Advanced 3D prostate Targeted Treatm …
The 3D Urology and Prostate Clinics is at the forefront of prostate care, offering the advanced 3D Targeted Therapy as a precise and effective treatment solution.
The 3D Urology and Prostate Clinics is proud to announce its revolutionary 3D prostate Targeted Treatment [http://www.3dprostatecure.com/page.php?cata_id=19], setting a new standard in prostate care. This highly advanced treatment option utilizes cutting-edge technology to deliver focused treatment, minimizing side effects and enhancing recovery for patients. Men…
3D Prostate Cure: Revolutionizing Prostate Treatment with Targeted Therapy
This news release highlights the 3D Urology and Prostate Clinics' innovative approach to prostate treatment using 3D Targeted Therapy, offering a safe and effective alternative to traditional methods.
As a global leader in men's health, The 3D Urology and Prostate Clinics is committed to providing cutting-edge treatments for various prostate conditions. The clinic is proud to announce its revolutionary 3D Targeted Therapy, offering a new standard in prostate care.
This innovative therapy…
The 3D Urology and Prostate Clinics Enhance Prostate Health with Advanced 3D Pro …
The 3D Urology and Prostate Clinics are revolutionizing prostate care with their comprehensive treatments, including the 3D prostate Targeted Treatment and 3D Targeted Therapy, developed to ensure effective, non-surgical solutions for prostate health issues.
At the forefront of prostate health, The 3D Urology and Prostate Clinics are excited to offer innovative treatments such as the 3D prostate Targeted Treatment and 3D Targeted Therapy. These treatments are part of the clinic's commitment…
